Capricor Therapeutics Expects Available Cash & Equivalents To Be Sufficient To Cover Anticipated Expenses And Capital Requirements Into Q1 Of 2025
Capricor Therapeutics Expects Available Cash & Equivalents To Be Sufficient To Cover Anticipated Expenses And Capital Requirements Into Q1 Of 2025
Capricor Therapeutics预计,可用现金及等价物将足以支付2025年第一季度的预期支出和资本需求
Capricor Therapeutics Expects Available Cash & Equivalents To Be Sufficient To Cover Anticipated Expenses And Capital Requirements Into Q1 Of 2025
Capricor Therapeutics预计,可用现金及等价物将足以支付2025年第一季度的预期支出和资本需求